Cite
HARVARD Citation
Oldroyd, A. et al. (n.d.). 219 Converting patients with chronic myositis from maintenance intravenous immunoglobulin therapy to rituximab in England: a potential saving of £1.7 million per year. Rheumatology. p. . [Online].